PD-L1 binding polypeptides for imaging

US10406251B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Paul E. Morin · Pennington, US
• David J. Donnelly · Doylestown, US
• Dasa Lipovsek · Pepperell, US
• Jochem Gokemeijer · Wayland, US
• Maria Jure-Kunkel · Plainsboro, US
• David Fabrizio · Hamilton, US
• Martin C. Wright · Belmont, US
• Douglas D. Dischino · Middlefield, US
• Samuel J. Bonacorsi, Jr. · Flemington, US
• Ralph Adam Smith · Yardley, US
• Virginie Lafont · Lawrence, US
• Daniel Cohen · Watertown, US

Key dates

• Filing date: Nov 24, 2015
• Grant date: Sep 10, 2019
• Expiry date: Nov 24, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/78
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.